ABSTRACT
OBJECTIVES: We aimed to evaluate the clinical response to cholestyramine in patients with functional chronic diarrhea and a high clinical suspicion of bile-acid diarrhea (BAD) investigated with 75-selenium homocholic acid taurine (SeHCAT) test. METHODS: Adult patients attending our outpatient clinic between January and December 2021 for chronic diarrhea with suspicion of BAD were proposed SeHCAT testing and a therapeutic trial of cholestyramine 4-8 g daily. Clinical response to cholestyramine was evaluated at 1, 3, 6, and 12 months. Clinical and demographic data were analyzed according to SeHCAT test results. RESULTS: Among the 50 patients with chronic diarrhea and clinical suspicion of BAD, 13 (26.0%) refused either SeHCAT testing or cholestyramine therapy. Finally, 37 patients (31 females, age 44 ± 14 years) agreed to undergo SeHCAT and were started on cholestyramine (median follow-up 14 months [interquartile range 6-16 months]). Initial response to cholestyramine was similar in patients with positive and negative SeHCAT test results, but improved over time in those with a positive test result. Long-term response (100% vs 65.2%, P = 0.02) and necessity of maintenance therapy for symptom control were more common in those with positive SeHCAT test result (71.4% vs 26.1%, P = 0.02). However, response to cholestyramine was also frequent in patients with a negative test result. CONCLUSIONS: The SeHCAT test accurately identifies patients with BAD who benefit from long-term cholestyramine treatment. Nevertheless, cholestyramine may be also effective in patients with chronic diarrhea but negative SeHCAT test result.
Subject(s)
Bile Acids and Salts , Cholestyramine Resin , Diarrhea , Humans , Female , Cholestyramine Resin/therapeutic use , Diarrhea/drug therapy , Male , Adult , Middle Aged , Prospective Studies , Chronic Disease , Bile Acids and Salts/metabolism , Taurocholic Acid/analogs & derivatives , Malabsorption Syndromes/diagnosis , Malabsorption Syndromes/drug therapy , Treatment Outcome , Selenium RadioisotopesABSTRACT
BACKGROUND: Dysregulation of bile acids (BAs) has been reported in alcohol-associated liver disease. However, the causal relationship between BA dyshomeostasis and alcohol-associated liver disease remains unclear. The study aimed to determine whether correcting BA perturbation protects against alcohol-associated liver disease and elucidate the underlying mechanism. METHODS: BA sequestrant cholestyramine (CTM) was administered to C57BL/6J mice fed alcohol for 8 weeks to assess its protective effect and explore potential BA targets. The causal relationship between identified BA metabolite and cellular damage was examined in hepatocytes, with further manipulation of the detoxifying enzyme cytochrome p450 3A11. The toxicity of the BA metabolite was further validated in mice in an acute study. RESULTS: We found that CTM effectively reversed hepatic BA accumulation, leading to a reversal of alcohol-induced hepatic inflammation, cell death, endoplasmic reticulum stress, and autophagy dysfunction. Specifically, nordeoxycholic acid (NorDCA), a hydrophobic BA metabolite, was identified as predominantly upregulated by alcohol and reduced by CTM. Hepatic cytochrome p450 3A11 expression was in parallel with NorDCA levels, being upregulated by alcohol and reduced by CTM. Moreover, CTM reversed alcohol-induced gut barrier disruption and endotoxin translocation. Mechanistically, NorDCA was implicated in causing endoplasmic reticulum stress, suppressing autophagy flux, and inducing cell injury, and such deleterious effects could be mitigated by cytochrome p450 3A11 overexpression. Acute NorDCA administration in mice significantly induced hepatic inflammation and injury along with disrupting gut barrier integrity, leading to subsequent endotoxemia. CONCLUSIONS: Our study demonstrated that CTM treatment effectively reversed alcohol-induced liver injury in mice. The beneficial effects of BA sequestrant involve lowering toxic NorDCA levels. NorDCA not only worsens hepatic endoplasmic reticulum stress and inhibits autophagy but also mediates gut barrier disruption and systemic translocation of pathogen-associated molecular patterns in mice.
Subject(s)
Bile Acids and Salts , Cholestyramine Resin , Liver Diseases, Alcoholic , Mice, Inbred C57BL , Animals , Mice , Cholestyramine Resin/pharmacology , Cholestyramine Resin/therapeutic use , Liver Diseases, Alcoholic/metabolism , Liver Diseases, Alcoholic/drug therapy , Liver Diseases, Alcoholic/prevention & control , Male , Bile Acids and Salts/metabolism , Liver/drug effects , Liver/metabolism , Endoplasmic Reticulum Stress/drug effects , Hepatocytes/drug effects , Hepatocytes/metabolism , Autophagy/drug effects , Disease Models, AnimalABSTRACT
BACKGROUND: Cholesterol levels and bile acid metabolism are important drivers of metabolic dysfunction-associated steatohepatitis (MASH) progression. Using a mouse model, we investigated the mechanism by which cholesterol exacerbates MASH and the effect of colestyramine (a bile acid adsorption resin) and elobixibat (an apical sodium-dependent bile acid transporter inhibitor) concomitant administration on bile acid adsorption and MASH status. METHODS: Mice were fed a high-fat high-fructose diet with varying concentrations of cholesterol to determine changes in fatty liver according to liver status, water intake, defecation status, insulin resistance, bile acid levels, intestinal permeability, atherosclerosis (in apolipoprotein E knockout mice), and carcinogenesis (in diethylnitrosamine mice). Using small interfering ribonucleic acid (siRNA), we evaluated the effect of sterol regulatory element binding protein 1c (SREBP1c) knockdown on triglyceride synthesis and fatty liver status following the administration of elobixibat (group E), colestyramine (group C), or both (group EC). RESULTS: We found greater reductions in serum alanine aminotransferase levels, serum lipid parameters, serum primary bile acid concentrations, hepatic lipid levels, and fibrosis area in EC group than in the monotherapy groups. Increased intestinal permeability and watery diarrhea caused by elobixibat were completely ameliorated in group EC. Group EC showed reduced plaque formation rates in the entire aorta and aortic valve of the atherosclerosis model, and reduced tumor counts and tumor burden in the carcinogenesis model. CONCLUSIONS: Excessive free cholesterol in the liver can promote fatty liver disease. Herein, combination therapy with EC effectively reduced free cholesterol levels in MASH model mice. Our study provides strong evidence for combination therapy as an effective treatment for MASH.
Subject(s)
Atherosclerosis , Non-alcoholic Fatty Liver Disease , Animals , Mice , Cholestyramine Resin/pharmacology , Cholestyramine Resin/therapeutic use , Bile Acids and Salts , Non-alcoholic Fatty Liver Disease/drug therapy , Disease Models, Animal , CarcinogenesisABSTRACT
OBJECTIVE: This study aims to understand the adverse drug reactions (ADRs) for non-statin antihyperlipidaemic drugs included in the China Anti-hyperlipidemic Drug Database. DESIGN: An approach of Chinese national database analysis was employed to screen clinical trials involving non-statin antihyperlipidaemic drugs from 1989 to 2019. SETTING: The database was provided by the China National Medical Products Administration Information Centre. PARTICIPANTS: In total, 117 clinical studies with 8800 patients were selected from 2650 clinical trials of the Anti-hyperlipidemic Drug Database. INTERVENTIONS: The non-statin antihyperlipidaemic drugs were divided into three groups: (1) fibrates (fenofibrate, gemfibrozil, bezafibrate, etofylline clofibrate); (2) nicotinic acid and derivatives (niacin, acipimox) and (3) others (probucol, cholestyramine). RESULTS: The results of this study show that first, gastrointestinal symptoms were the most common reactions (6.975%), which account for approximately 50% of the reported cases with ADRs. Second, cholestyramine (16.418%) and gemfibrozil (13.158%) were the most common gastrointestinal side effect-causing non-statin antihyperlipidaemic drugs, which account for one-third of the population. Third, niacin (7.879%) and gemfibrozil (5.000%) were the most likely cause of liver disease symptoms. Finally, niacin (10.909%) and acipimox (18.847%) were the major non-statin antihyperlipidaemic drugs with skin symptoms. CONCLUSION: This study revealed that gastrointestinal symptoms were the most common ADRs of fibrates, probucol and cholestyramine in the Chinese population. For nicotinic acid and derivatives, the ADRs of skin symptoms were the most common in China.
Subject(s)
Drug-Related Side Effects and Adverse Reactions , Niacin , Humans , Niacin/adverse effects , Gemfibrozil/therapeutic use , Probucol/therapeutic use , Cholestyramine Resin/therapeutic use , Hypolipidemic Agents/adverse effects , Fibric Acids/adverse effectsABSTRACT
BACKGROUND & AIMS: Bile acid sequestrants (BAS) may be a treatment in microscopic colitis (MC), but efficacy data are limited. We evaluated the effectiveness of BAS in MC and assessed the utility of bile acid testing to predict response. METHODS: Adults with MC treated with BAS (2010-2020) at Mayo Clinic were identified. Bile acid malabsorption was defined by elevated serum 7âº-hydroxy-4-cholesten-3-one or by fecal testing using previously validated cutoffs. Response was defined at 12 ± 4 weeks after BAS initiation as: complete (resolution of diarrhea), partial (≥50% improvement in diarrhea), nonresponse (<50% improvement), and intolerance (discontinuation due to side effects). Logistic regression was used to identify predictors of response to BAS. RESULTS: We identified 282 patients (median age, 59 years [range, 20-87 years]; 88.3% women) with median follow-up of 4.5 years (range, 0.4-9.1 years). Patients were treated with the following BAS: 64.9% cholestyramine, 21.6% colesevelam, and 13.5% colestipol. Clinical outcomes were: 49.3% complete response, 16.3% partial response, 24.8% nonresponse, and 9.6% intolerance. There were no differences in outcomes between those on BAS alone or BAS combined with other medications (P = .98). The dose of BAS was not associated with response (P = .51). Bile acid testing was done in 31.9% of patients, and 56.7% were positive. No predictors of response to BAS were identified. After BAS discontinuation, 41.6% had recurrence at a median of 21 weeks (range, 1-172 weeks). CONCLUSION: In one of the largest cohorts evaluating BAS treatment in MC, nearly two-thirds had a partial or complete response. Additional research is needed to determine the role of BAS and bile acid malabsorption in MC.
Subject(s)
Bile Acids and Salts , Colitis, Microscopic , Adult , Humans , Female , Middle Aged , Male , Cholestyramine Resin/therapeutic use , Diarrhea/drug therapy , Colitis, Microscopic/diagnosis , Colitis, Microscopic/drug therapy , Colestipol/therapeutic useABSTRACT
Pruritus can be associated with chronic liver disease, particularly cholestatic liver disease. Although the pathophysiology is uncertain, there are a few proposed mechanisms and much is still being discovered. Workup involves an assessment to rule out a dermatologic, neurologic, psychogenic, or other underlying systemic disorder. First-line therapy is cholestyramine, which is generally well tolerated and effective. In those who fail cholestyramine, alternative drugs including rifampicin and µ-opioid receptor antagonists can be considered. If medical therapy is ineffective and pruritus is significant, alternative experimental therapies such as albumin dialysis, photopheresis, plasmapheresis, and biliary diversion can be considered.
Subject(s)
Cholestasis , Liver Diseases , Humans , Cholestyramine Resin/therapeutic use , Pruritus/therapy , Pruritus/drug therapy , Liver Diseases/complications , Liver Diseases/therapy , Cholestasis/complications , Cholestasis/therapy , Narcotic Antagonists/therapeutic useABSTRACT
This case report deals with a patient managed in a tertiary-care cancer hospital who suffered pruritus associated with malignant cholestasis. His symptoms were resistant to conventional treatment with ursodeoxycholic acid, chlorpheniramine and cholestyramine. Hence, the multifactorial origin of malignancy-associated pruritus was considered. Correctable factors were corrected and generally the treatment was aimed at possible aetiologies. There were barriers related to insufficient resources available for symptom palliation in this particular setting, which could potentially reduce optimum symptom control. However, various pharmacotherapies and non-pharmacological measures which could potentially have helped relieve pruritus are described and future scope for research in this area discussed.
Subject(s)
Cholestasis , Humans , Cholestasis/complications , Cholestasis/drug therapy , Ursodeoxycholic Acid/therapeutic use , Cholestyramine Resin/therapeutic use , Pruritus/drug therapy , Pruritus/etiologyABSTRACT
Obesity is a risk factor for cerebrovascular diseases. Accumulating evidence has revealed that gut dysbiosis plays an important role in the pathophysiology of cerebrovascular diseases. However, little is known about the role of gut dysbiosis in stroke in obesity. In this study, we established a rodent middle cerebral artery occlusion (MCAO) model to investigate whether obesity-induced gut dysbiosis exacerbates cerebral ischemic injury and the role of the bile salt sequestrant cholestyramine resin (CR) in gut microbiota and stroke outcome in obese mice. Long-term 45% high-fat diet (HFD) diet (8 weeks) induced an obesity phenotype and caused gut dysbiosis, resulting in a larger infarct volume and higher serum levels of inflammatory cytokines after stroke, compared to those in the lean counterparts. LC-MS/MS and GC analysis revealed that obese mice with stroke developed an obviously perturbed bile acid (BA) profile characterized by higher levels of deoxycholic acid and its conjugated forms, and lower levels of butyrate in the cecal content. CR administration improved the obesity-induced dysbiotic microbiome, attenuated ischemic brain injury and modulated the stroke-perturbed BA profile. Furthermore, fecal microbiota transplantation (FMT) experiments revealed that the impact of obesity on stroke and the neuroprotective effects of CR were mediated by gut microbiota. In conclusion, Obesity induces gut dysbiosis, worsens stroke outcomes, and perturbs the BA profile. The dysbiotic microbiome is an important linkage between obesity and stroke. CR confers metabolic benefits and neuroprotective effects in obesity, perhaps by modulating gut microbial composition and BA metabolism.
Subject(s)
Brain Injuries , Neuroprotective Agents , Stroke , Mice , Animals , Dysbiosis/complications , Dysbiosis/metabolism , Mice, Obese , Bile Acids and Salts , Cholestyramine Resin/therapeutic use , Chromatography, Liquid , Tandem Mass Spectrometry , Obesity/complications , Stroke/complications , Brain Injuries/complicationsABSTRACT
Pruritus in cholestatic liver diseases can be a major burden and dramatically impair the quality of life of those affected. Here, we provide an update on the latest insights into the molecular pathogenesis of and novel therapeutic approaches for cholestasis-associated itch. Endogenous and exogenous small-molecule pruritogen candidates bind to their receptors on unmyelinated itch C-fibres in the skin. Candidate pruritogens in cholestasis include certain lysophospholipids and sulfated progesterone metabolites, among others, whereas total bile acid or bilirubin conjugates seem unlikely to have a dominant role in the pathogenesis of cholestasis-associated pruritus. Transmission of itch signals via primary, secondary and tertiary itch neurons to the postcentral gyrus and activation of scratch responses offer various targets for therapeutic intervention. At present, evidence-based treatment options for pruritus in fibrosing cholangiopathies, such as primary biliary cholangitis and primary sclerosing cholangitis, are the peroxisome proliferator-associated receptor (PPAR) agonist bezafibrate and the pregnane X receptor (PXR) agonist rifampicin. In pruritus of intrahepatic cholestasis of pregnancy, ursodeoxycholic acid is recommended and might be supported in the third trimester by rifampicin if needed. Alternatively, non-absorbable anion exchange resins, such as cholestyramine, can be administered, albeit with poor trial evidence. Liver transplantation for intolerable refractory pruritus has become an extremely rare therapeutic strategy.
Subject(s)
Cholestasis, Intrahepatic , Cholestasis , Pregnancy , Female , Humans , Rifampin/therapeutic use , Quality of Life , Cholestasis/complications , Cholestasis/metabolism , Pruritus/drug therapy , Pruritus/etiology , Cholestyramine Resin/therapeutic use , Cholestasis, Intrahepatic/drug therapyABSTRACT
PURPOSE: Immune checkpoint inhibitors (ICI) are effective against various malignancies. However, adverse events including diarrhea and colitis can lead to significant morbidity and mortality. Recommendations for the management of ICI mediated diarrhea and colitis include steroids and biologics. Given their associated risks, this study evaluated the role of the non-immunosuppressive agents, mesalamine and or cholestyramine. METHODS: This is a retrospective, descriptive, single-center study of adults who developed ICI diarrhea and colitis between 2010 and 2020 at MD Anderson Cancer Center. Clinical data and outcomes were compared between those treated with the non-immunosuppressive therapies mesalamine and/or cholestyramine alone versus those who received additional immunosuppression with steroids and biologics. RESULTS: Our sample comprised 66 patients wherein, the mean age was 63 years, 71% were males, and 97% had stage III/IV cancers. Fourteen patients were treated successfully with non-immunosuppressive therapy. They had grade 1-3 diarrhea and 1-2 colitis with no difference in the rate of histologic colitis compared to those who received immunosuppressive therapy. They had less CTLA-4 inhibitor-based therapy (36% vs. 73%, p = 0.034), delayed onset of symptoms (159 vs. 64 days, p = 0.011), lower fecal calprotectin levels (56 vs. 234, p = 0.012) and were more likely to resume ICI therapy (64% vs. 25%, p = 0.006). CONCLUSION: Mesalamine and/or cholestyramine may be effective for mild ICI diarrhea and colitis among patients with delayed symptom onset with lower colonic inflammatory burden. Prospective studies randomizing patients with mild colitis between mesalamine/cholestyramine and immunosuppressive treatment are warranted to assess their efficacy and safety.
Subject(s)
Colitis , Mesalamine , Male , Adult , Humans , Middle Aged , Female , Mesalamine/adverse effects , Cholestyramine Resin/therapeutic use , Immune Checkpoint Inhibitors/therapeutic use , Retrospective Studies , Prospective Studies , Colitis/chemically induced , Colitis/drug therapy , Diarrhea/chemically induced , Diarrhea/drug therapy , Immunosuppressive Agents/therapeutic useABSTRACT
BACKGROUND The therapeutic approach to Graves' disease (GD) comprises thionamides, radioiodine ablation, or surgery as first-line therapy, and cholestyramine and oral iodine as second-line therapies. The role of lithium (Li) in GD as a primary or adjunctive therapy remains contentious. We present a case of GD managed by Li therapy with oral iodine solution. CASE REPORT A 26-year-old man, admitted with acute blast crisis secondary to chronic myeloid leukemia (CML), reported palpitations, 40-lb weight loss, heat intolerance, and fatigue. An examination revealed sinus tachycardia, elevated body temperature, and thyromegaly. Laboratory evaluation confirmed hyperthyroidism (TSH <0.005 mcIU/l, FT4 5.57 ng/dl, TT3 629 ng/dl) secondary to GD (TRAb >40 IU/l, TSIg 178%). Thionamides and surgery were contraindicated due to pancytopenia from a blast crisis. Inability to maintain post-radiation precautions precluded use of RAI. Cholestyramine was attempted and discontinued due to nausea. We introduced oral Li carbonate with oral iodine, which the patient tolerated. Thyroid functions improved with therapy (TSH 0.007 mcIU/l, FT4 0.82 ng/dl, TT3 122 ng/dl) with stable Li level (0.5-0.8 mmol/l). CONCLUSIONS Li inhibits iodine uptake through interference with sodium-iodide symporter and tyrosine iodination, thyroglobulin structure changes, peripheral deiodinase blockage, and preventing TSH and TSIg stimulation. Our case shows that a low therapeutic level of Li, in combination with oral iodine, can suppress thyroid overactivity without adverse effects. We suggest that low-dose Li carbonate is a safe and effective adjunctive antithyroid medication to be considered if primary therapies for hyperthyroidism are unavailable.
Subject(s)
Graves Disease , Hyperthyroidism , Iodine , Adult , Blast Crisis , Carbonates/therapeutic use , Cholestyramine Resin/therapeutic use , Graves Disease/complications , Graves Disease/diagnosis , Graves Disease/drug therapy , Humans , Hyperthyroidism/complications , Hyperthyroidism/etiology , Iodine/therapeutic use , Iodine Radioisotopes/therapeutic use , Lithium/therapeutic use , Male , ThyrotropinABSTRACT
INTRODUCCIÓN: Este documento técnico se realizó en el marco de la Guía de Práctica Clínica para pacientes pediátricos con falla intestinal; la pregunta PICO fue la siguiente: P: pacientes de 0-18 años con resección ileal por cualquier causa; I: colestiramina; C: placebo, colestipol, colesevelam, dietas modificadas o suplementos dietéticos; O: frecuencia de deposiciones, cambio en el peso o masa de las heces y eventos adversos. a. Cuadro clínico: Los ácidos biliares son moléculas cuya función principal es ayudar en la digestión y absorción de lípidos. En personas sanas, más del 95% de ácidos biliares se reabsorben en el íleon terminal. La reabsorción insuficiente de ácidos biliares en el íleon terminal incrementa la concentración en el colon, produciendo diarrea secretora. Se estima que la malabsorción de ácidos biliares (MAB) afecta al 1% de la población de países occidentales y cerca del 90% de pacientes con resección ileal. El tratamiento de la diarrea por MAB consiste en un manejo dietético y farmacológico. Los pacientes con diarrea y esteatorrea moderada deben someterse a una dieta baja en grasas (30 g/día) con o sin adición de triglicéridos de cadena media. El tratamiento farmacológico se basa en secuestrantes de ácidos biliares como colestiramina, colestipol o colesevelam. b. Tecnología sanitaria: Colestiramina es un secuestrante de ácidos biliares que se une con alta afinidad a los ácidos biliares en el intestino para formar un complejo estable e insoluble que se excreta en las heces. Pese a no ser una indicación aprobada, se emplea hace varias décadas para el tratamiento de MAB. Su forma de presentación consiste en sachets conteniendo 4 gr de polvo. Las dosis empleadas para la diarrea por MAB deben adaptarse a la respuesta del paciente, con una dosis máxima de 36 gr al día. Los eventos adversos suelen ser dependientes de la dosis, siendo los más frecuentes: malestar gastrointestinal, dispepsia, flatulencia, estreñimiento, náuseas y vómitos. Colestiramina cuenta en Perú con un registro sanitario vigente. Según el observatorio de precios de medicamentos de DIGEMID, el costo más bajo en el sector privado de 100 sobres de colestiramina asciende a S/. 13.00 (S/. 0.13 por cada sobre) mientras que no se hallaron precios disponibles en el sector público. OBJETIVO: Describir la evidencia científica sobre la eficacia y seguridad de colestiramina para el tratamiento de diarrea por malabsorción de ácidos biliares secundaria a resección ileal en población pediátrica. METODOLOGÍA: La búsqueda de evidencia se desarrolló en Medline, Web of Science, The Cochrane Library y LILACS hasta el 04 de octubre de 2021, limitado a estudios en español o inglés. La búsqueda de guías de práctica clínica (GPC) y evaluaciones de tecnología sanitaria (ETS) se desarrolló en repositorios digitales de agencias elaboradoras de estos documentos. Adicionalmente, se realizó una búsqueda de GPC en PubMed. Se valoró el riesgo de sesgo empleado la herramienta de la Colaboración Cochrane. RESULTADOS: No se identificó ningún estudio en población pediátrica. Se consideró como evidencia indirecta cuatro estudios primarios desarrollados en adultos. Frecuencia de deposiciones: El estudio de Hofmann (1969) reportó una reducción en la frecuencia diaria de deposiciones (p<0.05) durante el tratamiento con colestiramina en pacientes con <100 cm de resección ileal, comparado con placebo. En pacientes con >100 cm de íleon resecado (n=8) no se observaron diferencias. Un segundo estudio de Hofmann (1972) reportó una disminución en la frecuencia de deposiciones diarias de pacientes con resección ileal <100 cm tratados con colestiramina y triglicéridos de cadena larga (TCL) o media (TCM), en comparación con solo TCL o TCM. En pacientes con resección ileal >100 cm, colestiramina redujo la frecuencia de deposiciones, aunque la mayor reducción se observó cuando se reemplazó TCL por TCM, ambos sin colestiramina (p<0.025). El estudio de Jacobsen reportó una reducción del número de evacuaciones fecales durante el tratamiento con colestiramina comparado con placebo (15 vs 23, p<0.05). El estudio de Williams reportó una disminución del número de deposiciones al día en pacientes tratados colestiramina comparado con una dieta control (2.3 vs 4.6; p=0.027). Volumen de masa fecal El estudio de Hofmann (1969) reportó que 4 de 6 pacientes con <100 cm de resección ileal alcanzaron una reducción significativa de la masa fecal comparado con placebo (p<0.05). En pacientes con >100 cm de íleon resecado (n=3), colestiramina no produjo reducción significativa de la masa fecal en ningún participante. El estudio de Jacobsen reportó una reducción del volumen de masa fecal durante el tratamiento con colestiramina comparado con placebo (p<0.05). El estudio de Williams reportó una disminución significativa de la masa fecal en pacientes tratados colestiramina comparado con una dieta control de 2000 Kcal con TCL (media: 394 gr/día vs 568 gr/día; p=0.027). Eventos adversos: Ningún estudio informó sobre la presencia de eventos adversos. Recomendaciones en GPC: Las GPC de la Asociación Argentina de Nutrición Enteral y Parenteral (AANEP) y de la Canadian Association of Gastroenterology (CAG) recomiendan colestiramina para el manejo de la MAB. Las GPC de la European Society for Clinical Nutrition and Metabolism (ESPEN), Cleveland Clinic, British Society of Gastroenterology (BSG), y American Gastroenterological Association (AGA) no recomiendan su uso en pacientes con resección ileal extensa. Evaluaciones de Tecnología Sanitaria: Una ETS desarrollada por IETSI concluyó con evidencia limitada aprobar el uso de colestiramina para el tratamiento de pacientes con diarrea crónica por MAB. Sin embargo, su aprobación fue revocada un año después por tratarse de una indicación terapéutica "fuera de etiqueta". Evaluación de la calidad metodológica: Tres estudios tuvieron alto riesgo de sesgo de selección. Dos estudios tuvieron alto riesgo de sesgo de realización y detección. El riesgo de sesgo de reporte fue considerado poco claro en todos los estudios. Todos los estudios fueron considerados como alto riesgo de otro tipo de sesgos por un reporte insuficiente o nulo de las fuentes de financiamiento y el conflicto de interés de los autores. CONCLUSIONES: Los hallazgos sobre la eficacia de colestiramina no fueron concluyentes. Dos estudios reportaron una reducción en la frecuencia de deposiciones y volumen fecal en pacientes tratados con colestiramina, mientras que otros dos estudios mostraron una reducción significativa solo en pacientes con resección ileal <100 cm, y un efecto limitado o nulo en pacientes con resección ileal extensa (>100 cm). No se informaron resultados sobre la seguridad de colestiramina. Los estudios incluidos enrolaron un número pequeño de participantes, con periodos cortos de seguimiento, presentaron alta heterogeneidad en el diseño, características de los participantes e intervenciones, y tuvieron un alto riesgo de sesgo en la mayoría de dimensiones evaluadas. Dos GPC consideran el uso de colestiramina como terapia para pacientes con diarrea por MAB, mientras que cuatro GPC recomiendan limitar su uso en pacientes con resección ileal extensa. Una ETS realizada por IETSI (Perú) concluyó aprobar el uso de colestiramina para el tratamiento de pacientes con diarrea crónica por MAB. Sin embargo, su aprobación fue revocada un año después por tratarse de una indicación terapéutica "fuera de etiqueta".
Subject(s)
Humans , Child , Bile Acids and Salts/deficiency , Cholestyramine Resin/therapeutic use , Diarrhea, Infantile/drug therapy , Intestinal Absorption , Efficacy , Cost-Benefit AnalysisABSTRACT
Amiodarone is a class 3 antiarrhythmic drug which may be associated with thyroid dysfunction. Amiodarone-induced thyrotoxicosis (AIT) is classified as type 1 (AIT 1; which may develop in the presence of latent autoimmune hyperthyroid condition) or type 2 (AIT 2; which develops in an apparently normal thyroid resulting from destructive thyroiditis). AIT 1 routinely requires treatment with thionamides, whereas AIT 2 is treated with steroids. Resistance to the conventional treatment of hyperthyroidism is not commonly found in clinical practice. This report discusses a case of AIT 2 resistant to conventional treatment. Despite being on high doses of carbimazole and steroids (prednisolone), the patient remained thyrotoxic. Cholestyramine, a bile salt sequestrant, was used as an adjunctive therapy resulting in significant clinical and biochemical improvement. The patient subsequently became euthyroid and is being followed up in endocrine clinic.
Subject(s)
Amiodarone , Thyrotoxicosis , Amiodarone/adverse effects , Anti-Arrhythmia Agents/adverse effects , Cholestyramine Resin/therapeutic use , Humans , Thyrotoxicosis/chemically induced , Thyrotoxicosis/drug therapyABSTRACT
Autosomal recessive hypercholesterolemia (ARH) is a rare form of genetic hypercholesterolemia caused by mutations in low density lipoprotein receptor adaptor protein 1 (LDLRAP1). The proband first presented with linear eruptive xanthomas over her ankles, knees and elbows, with low density lipoprotein cholesterol (LDL-C) of 16.0 mmol/L (618.7 mg/dL), at 2.5 years old. Next generation sequencing revealed a novel homozygous mutation in LDLRAP1 exon 5 (c.466delG). In the first year, drug regimens of either cholestyramine or simvastatin, reduced her LDL-C to 10.5 mmol/L (406 mg/dL) and 11.7 mmol/L (452.4 mg/dL), respectively. Combination simvastatin and ezetimibe was the mainstay of therapy from age 5 - 10 years. Her lowest achieved LDL-C was 6.3 mmol/L (243.6 mg/dL). Switching to atorvastatin did not lead to further reduction. Carotid intima-media thickness was 0.47 mm (> 97th percentile) and 0.32 mm (75 - 95th percentile) at ages 8 years and 11 years, respectively. Addition of monthly injections of evolocumab for 3 months, led to an increase in LDL-C, from 7.0 mmol/L (270.7 mg/dL) to a range of [(8.4 - 9.1) mmol/L or (324.8 - 351.9) mg/dL]. In this report, a decade-long lipid management is described in a patient with ARH. Residual activity of LDLRAP1 is a likely determinant of her response. Clinical management remains sub-optimal and options for the paediatric population are limited. Novel classes of cholesterol-lowering medications are needed for this ultra-rare and severe hypercholesterolemia.
Subject(s)
Anticholesteremic Agents/therapeutic use , Cholestyramine Resin/therapeutic use , Ezetimibe/therapeutic use , Genes, Recessive , Homozygote , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Hypercholesterolemia/drug therapy , Hypercholesterolemia/genetics , Child , Female , Humans , Male , PedigreeABSTRACT
BACKGROUND: Longer serum half-lives of perfluoroalkyl substances (PFAS) in humans compared to other species has been attributed to differences in the activity of organic anion transporters (OAT). METHODS: Among 56,175 adult participants in the community-based C8 Health Project, 23 subjects were taking the uricosuric OAT-inhibitor probenecid, and 36 subjects were taking the bile acid sequestrant cholestyramine. In regression models of log transformed serum PFAS, medication effects were estimated in terms of mean ratios, adjusting for age, gender, BMI, estimated glomerular filtration rate (eGFR) and water-district of residence. RESULTS: Probenecid was associated with modest, but not statistically significant increases in serum PFAS concentrations. In contrast, cholestyramine significantly lowered serum PFAS concentrations, notably for perfluorooctane sulfonic acid (PFOS). CONCLUSIONS: The effectiveness of cholestyramine in a community setting supports the importance of gastrointestinal physiology for PFAS excretion kinetics, especially for PFOS. We did not find clear evidence that probenecid, an inhibitor of OAT, affects PFAS clearance.
Subject(s)
Anticholesteremic Agents/therapeutic use , Cholestyramine Resin/therapeutic use , Environmental Pollutants/blood , Fluorocarbons/blood , Organic Anion Transporters/antagonists & inhibitors , Probenecid/therapeutic use , Sulfonic Acids/blood , Uricosuric Agents/therapeutic use , Adult , Aged , Female , Humans , Male , Middle AgedABSTRACT
BACKGROUND: Bile acid malabsorption occurs in up to one third of patients with chronic diarrhoea of functional characteristics. The gold standard test for its diagnosis is the 75Selenium homocholic acid taurine (75SeHCAT) test. The aim of this work is to confirm previous data suggesting that bile acid malabsorption, diagnosed by 75Se-HCAT test, is the underlying cause of diarrhoea in a significant proportion of patients previously diagnosed with a functional disorder. In addition, we have analysed the clinical response of bile acid sequestrants in those patients with a bile acid diarrhoea diagnosis. METHODS: This is a prospective, single-centre study including consecutive adult patients diagnosed with chronic diarrhoea of unknown origin and with functional characteristics; systematic rule out of common causes of chronic diarrhoea was performed before bile acid malabsorption evaluation by 75SeHCAT scanning. A retention percentage less than 10% was considered positive. Clinical response to cholestyramine was further evaluated in those patients with a positive diagnosis of bile acid diarrhoea RESULTS: 38 patients (20 male, mean age 37.5 years) were finally included. Twenty (52.6%) patients included had a positive 75SeHCAT test. Median body mass index was significantly higher in those patients. We did not find significant differences in other clinical or biochemical variables 75SeHCAT-positive and 75SeHCAT-negative groups. Only 6 of 17 (35.3%) patients responded to cholestyramine treatment; 10 patients did not have response or withdraw the drug due to adverse events. Logistic regression analysis showed that none of the included variables was a predictor of clinical response to cholestyramine. CONCLUSIONS: Bile acid malabsorption occurs in a high proportion of patients suffering from chronic diarrhoea with functional characteristics. Systematic investigation of bile acid malabsorption should be included in the diagnostic algorithms of patients with chronic watery diarrhoea in the routine clinical practice. Absence of response to cholestyramine does not rule out bile acid diarrhoea.
Subject(s)
Bile Acids and Salts , Cholestyramine Resin , Adult , Cholestyramine Resin/therapeutic use , Diarrhea/epidemiology , Diarrhea/etiology , Humans , Male , Prevalence , Prospective Studies , Taurocholic AcidABSTRACT
WHAT IS KNOW AND OBJECTIVE: Teriflunomide is indicated for the treatment of adult patients with relapsing-remitting multiple sclerosis. CASE SUMMARY: We present a rare intoxication with a high dose (672 mg) of teriflunomide. According to its product label, the only known treatment is the administration of colestyramine and activated carbon (charcoal). No serious adverse events occurred during the time the patient was admitted (<24 h). No long-term overdose-related symptoms or complaints were reported. WHAT IS NEW AND CONCLUSION: The fact that after the acute overdose both adverse events and laboratory parameters were acceptable, prescribing colestyramine and activated carbon, as well as monitoring of laboratory parameters such as full blood count, liver and kidney values and QTc, seems sufficient during the early stage (<24 h after intake) of teriflunomide overdose.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/toxicity , Crotonates/toxicity , Drug Overdose/physiopathology , Hydroxybutyrates/toxicity , Nitriles/toxicity , Toluidines/toxicity , Adult , Antidotes/therapeutic use , Charcoal/therapeutic use , Cholestyramine Resin/therapeutic use , Drug Overdose/drug therapy , Humans , MaleABSTRACT
A key challenge in antibiotic stewardship is figuring out how to use antibiotics therapeutically without promoting the evolution of antibiotic resistance. Here, we demonstrate proof of concept for an adjunctive therapy that allows intravenous antibiotic treatment without driving the evolution and onward transmission of resistance. We repurposed the FDA-approved bile acid sequestrant cholestyramine, which we show binds the antibiotic daptomycin, as an 'anti-antibiotic' to disable systemically-administered daptomycin reaching the gut. We hypothesized that adjunctive cholestyramine could enable therapeutic daptomycin treatment in the bloodstream, while preventing transmissible resistance emergence in opportunistic pathogens colonizing the gastrointestinal tract. We tested this idea in a mouse model of Enterococcus faecium gastrointestinal tract colonization. In mice treated with daptomycin, adjunctive cholestyramine therapy reduced the fecal shedding of daptomycin-resistant E. faecium by up to 80-fold. These results provide proof of concept for an approach that could reduce the spread of antibiotic resistance for important hospital pathogens.
Antibiotics are essential for treating infections. But their use can inadvertently lead to the emergence of antibiotic-resistant bacteria that do not respond to antibiotic drugs, making infections with these bacteria difficult or impossible to treat. Finding ways to prevent antibiotic resistance is critical to preserving the effectiveness of antibiotics. Many bacteria that cause infections in hospitals live in the intestines, where they are harmless. But these bacteria can cause life-threatening infections when they get into the bloodstream. When patients with bloodstream infections receive antibiotics, the bacteria in their intestines are also exposed to the drugs. This can kill off all antibiotic-susceptible bacteria, leaving behind only bacteria that have mutations that allow them to survive the drugs. These drug-resistant bacteria can then spread to other patients causing hard-to-treat infections. To stop this cycle of antibiotic treatment and antibiotic resistance, Morley et al. tested whether giving a drug called cholestyramine with intravenous antibiotics could protect the gut bacteria. In the experiments, mice were treated systemically with an antibiotic called daptomycin, which caused the growth of daptomycin-resistant strains of bacteria in the mice's intestines. In the laboratory, Morley et al. discovered that cholestyramine can inactivate daptomycin. Giving the mice cholestyramine and daptomycin together prevented the growth of antibiotic-resistant bacteria in the mice's intestines. Moreover, cholestyramine is taken orally and is not absorbed into the blood. It therefore only inactivates the antibiotic in the gut, but not in the blood. The experiments provide preliminary evidence that giving cholestyramine with antibiotics might help prevent the spread of drug resistance. Cholestyramine is already used to lower cholesterol levels in people. More studies are needed to determine if cholestyramine can protect gut bacteria and prevent antibiotic resistance in people.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Cholestyramine Resin/therapeutic use , Daptomycin/antagonists & inhibitors , Daptomycin/therapeutic use , Drug Resistance, Bacterial , Enterococcus faecium/drug effects , Animals , Anti-Bacterial Agents/pharmacology , Chemotherapy, Adjuvant , Cholestyramine Resin/pharmacology , Daptomycin/pharmacology , Drug Interactions , Female , Gastrointestinal Diseases/microbiology , Gastrointestinal Diseases/prevention & control , Gram-Positive Bacterial Infections/microbiology , Gram-Positive Bacterial Infections/prevention & control , Mice , Mice, Inbred C57BLABSTRACT
INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) pathogenesis involves abnormal metabolism of cholesterol and hepatic accumulation of toxic free-cholesterol. Elobixibat (EXB) inhibits the ileal bile acid (BA) transporter. EXB and cholestyramine (CTM) facilitate the removal of free cholesterol from the liver by decreasing BA recirculation to the liver, thereby stimulating novel BA synthesis from cholesterol. In this randomised, double-blind, placebo-controlled, parallel-group, phase IIa study, we aim to provide a proof-of-concept assessment by evaluating the efficacy and safety of EXB in combination with CTM in patients with NAFLD. METHODS AND ANALYSIS: A total of 100 adult patients with NAFLD, diagnosed based on low-density lipoprotein cholesterol (LDL-C) level of >120 mg/dL and liver fat content of ≥8% by MRI-based proton density fat fraction (MRI-PDFF), who meet the inclusion/exclusion criteria will be enrolled. The patients will be randomly assigned to receive the combination therapy of 10 mg EXB and 9 g CTM powder (4 g CTM), 10 mg EXB monotherapy, 9 g CTM powder monotherapy or a placebo treatment (n=25 per group). Blood tests and MRIs will be performed 16 weeks following treatment initiation. The primary study endpoint will be the absolute LDL-C level change at week 16 after treatment initiation. The exploratory endpoint will include absolute changes in the liver fat fraction as measured by MRI-PDFF. This proof-of-concept study will determine whether the combination therapy of EXB and CTM is effective and safe for patients with NAFLD. ETHICS AND DISSEMINATION: Ethics approval was obtained from the Ethics Committee of Yokohama City University Hospital before participant enrolment. The results of this study will be submitted for publication in international peer-reviewed journals and the key findings will be presented at international scientific conferences. TRIAL REGISTRATION NUMBER: NCT04235205.
Subject(s)
Non-alcoholic Fatty Liver Disease , Thiazepines , Adult , Cholestyramine Resin/therapeutic use , Clinical Trials, Phase II as Topic , Dipeptides , Double-Blind Method , Humans , Non-alcoholic Fatty Liver Disease/diagnostic imaging , Non-alcoholic Fatty Liver Disease/drug therapy , Proof of Concept Study , Randomized Controlled Trials as TopicABSTRACT
RATIONALE: Teriflunomide is a disease-modifying drug that has been approved for treatment of relapsing-remitting multiple sclerosis. Due to its teratogenic effect in animals, however, it is not recommended during pregnancy. For this reason, effective contraception must be used during its administration. When an unscheduled pregnancy occurs during therapy, patients must undergo a cholestyramine procedure for rapid flushing of the drug. PATIENT CONCERNS: We describe the case of a 35-year-old female patient suffering diagnosed with relapsing-remitting multiple sclerosis at the age of 20. The patient as a result of side effects of previous therapies started taking teriflunomide. DIAGNOSIS: Despite recommendations for the use of contraceptives, the patient became pregnant during drug therapy. Pregnancy occurred 12 months after initiating teriflunomide treatment. INTERVENTIONS: Therapy with teriflunomide was immediately suspended and cholestyramine was prescribed (8âg 3 times a day, for 11 days) to flush out any residual drug from the body. OUTCOMES: Despite an 8-week exposure to teriflumomide during gestation, the patient gave birth to healthy twin girls at 35 week. Controls carried out after birth did not reveal any malformation or genetic and chromosomal abnormality. At a 5-month pediatric specialist check both babies were healthy and growing regularly. CONCLUSION: This shows that even if there is evidence of teratogenic effects in animals, an 8-week exposure to teraflunomide >0.02âmg/L did not have effects on the newborn.